MMC
Marsh & McLennan Companies, Inc.187.17
-0.13-0.07%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
92.02BP/E (TTM)
22.42Basic EPS (TTM)
8.35Dividend Yield
0.02%Recent Filings
8-K
Q3 revenue up 11%, rebranding announced
Marsh McLennan reported Q3 2025 revenue of $6.4 billion, up 11% from last year, with 4% underlying growth; adjusted operating income climbed 13% to $1.4 billion, and adjusted EPS rose 11% to $1.85. The firm unveiled a rebranding to Marsh starting January 2026, plus a new Business and Client Services unit to boost innovation and efficiency amid complex markets. Repurchased $400 million in shares. Thrive program risks could temper gains.
10-Q
Q3 FY2025 results
Marsh McLennan posted solid Q3 results, with revenue climbing 11% year-over-year to $6.4 billion, driven by 13% growth in Risk and Insurance Services and 9% in Consulting, though underlying growth tempered to 4% amid currency headwinds. Operating income edged up 6% to $1.2 billion, but margins slipped slightly to 18.4% as expenses rose 13% on acquisitions like McGriff and higher compensation; diluted EPS held steady at $1.51. Cash swelled to $2.5 billion, bolstered by $3.1 billion in operating cash flow, while total debt sits at $19.6 billion with full revolver availability. The Thrive program launched, eyeing $400 million in annual savings over three years. Yet regulatory scrutiny in insurance broking lingers as a key risk.
8-K
Q2 revenue surges 12%
Marsh McLennan posted Q2 revenue of $7.0 billion, up 12% year-over-year, with 4% underlying growth fueled by acquisitions like McGriff. Adjusted operating income climbed 14% to $2.1 billion, while adjusted EPS rose 11% to $2.72. The board hiked the quarterly dividend 10% to $0.90 per share. Momentum persists amid integration costs.
10-Q
Q2 FY2025 results
Marsh & McLennan posted solid Q2 results, with revenue climbing 12% year-over-year to $7.0B, fueled by 15% growth in Risk and Insurance Services from strong Marsh renewals and McGriff integration, while Consulting edged up 7% on steady Mercer health demand. Operating income rose 11% to $1.8B, lifting diluted EPS 8% to $2.45 amid higher interest costs from debt; margins held firm at 26.2% despite acquisition expenses. Cash from operations hit $1.0B year-to-date, bolstering $1.7B liquidity with no revolver draws, yet total debt sits at $19.7B including recent issuances for buys. Acquisitions added $100M goodwill this half, but cyber threats loom large.
8-K
Broussard joins MMC board
Marsh McLennan appointed Bruce Broussard, 63, as an independent director effective July 9, 2025, expanding the board to 12 members and assigning him to the Audit Committee. Broussard brings over 30 years in healthcare and insurance, including CEO roles at Humana from 2013 to 2024 and McKesson Specialty/US Oncology. His expertise bolsters the board's insights on key sector issues. Yet, integration of his perspective remains to be seen.
IPO
Employees
Sector
Industry
AJG
Arthur J. Gallagher & Co.
251.98-4.21
AON
Aon plc
351.80-2.30
BRO
Brown & Brown, Inc.
80.97-1.36
MC
Moelis & Company
69.37-0.04
MFC
Manulife Financial Corporation
35.92+0.16
MKL
Markel Group Inc.
2140.70-19.52
MMI
Marcus & Millichap, Inc.
27.95+0.17
RYAN
Ryan Specialty Holdings, Inc.
53.00-1.19
TIRX
TIAN RUIXIANG Holdings Ltd
0.55-0.04
WTW
Willis Towers Watson Public Lim
329.76-1.01